Business, energy, technology, markets and global industry news from Business News Today

ASC30

PharmaDeviceNews ASC30
Infographic showing Ascletis’ early clinical results for oral ASC30, highlighting up to a 1.7-percentage-point reduction in HbA1c, 4.4% weight loss and the need for larger trials to confirm safety and efficacy.
Pharma & Biotech

Can Ascletis ASC30 compete with established oral GLP-1 treatments?

Ascletis reports up to 1.7-point HbA1c reduction and 4.4% weight loss with oral ASC30, as larger trials must confirm safety and efficacy.

Read More
Representative image of an oral obesity treatment concept illustrating how Eli Lilly and Company’s Foundayo approval could widen access to GLP-1 weight loss therapy and reshape the next phase of the obesity drug market.
Pharma & Biotech

Ascletis starts 4,600-patient Phase 3 trial of oral GLP-1 weight-loss drug ASC30

Ascletis Pharma has dosed the first participant in a 4,600-person global Phase 3 program for ASC30, a once-daily oral small-molecule GLP-1 receptor agonist that produced up to 7.7% placebo-adjusted weight loss after 13 weeks in Phase 2.

Read More
Pharma & Biotech

Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?

Oral GLP-1s promise convenience, but proof is still clinical. Ascletis’ ASC30 diabetes trial could test whether hype can meet HbA1c data.

Read More
Pharma & Biotech

Is oral GLP-1 finally viable? Inside Ascletis Pharma’s U.S. trial for ASC30

Ascletis starts U.S. Phase II trial of ASC30 in type 2 diabetes. Find out what this oral GLP-1R agonist could mean for the future of metabolic therapies.

Read More